A5092180825- Protease and Inhibitor Mechanisms
- Cell Adhesion Molecules Research
- Angiogenesis and VEGF in Cancer
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Mechanisms of cancer metastasis
- Renal and related cancers
- Galectins and Cancer Biology
- Extracellular vesicles in disease
- Bone health and treatments
- Ovarian cancer diagnosis and treatment
- Bone Metabolism and Diseases
- Bone health and osteoporosis research
Osaka University
2023-2024
RNA interference is a powerful gene-silencing tool with potential clinical applications. However, its therapeutic use challenging because suitable carriers are unavailable. Exosomes stable small endogenous vesicles that can transport functional molecules to target cells, making them ideal interfering (siRNA) carriers. Herein, we elucidated the of patient-derived exosomes as an siRNA carrier for ovarian cancer (OC) treatment. The were extracted from culture medium primary fibroblasts...
Abstract Although bevacizumab (BEV) plays a key role in ovarian cancer treatment, BEV resistance is often observed clinical settings. This study aimed to identify the genes responsible for resistance. C57BL/6 mice inoculated with ID-8 murine cells were treated anti-VEGFA antibody or IgG (control) twice weekly 4 weeks. The sacrificed, then, RNA was extracted from disseminated tumors. qRT-PCR assays performed angiogenesis-related and miRNAs that altered by treatment. SERPINE1/PAI-1 found be...
Abstract Background : Globally there has been an increase in the number of patients receiving long-term antiresorptive drugs for treatment postmenopausal osteoporosis; however, is little evidence to guide decisions regarding when and how stop or switch drugs. In this prospective observational study, we investigated efficacy romosozumab women treated with conventional osteoporosis more than 3 years. Methods: Despite 36 months osteoporosis, lumbar femoral neck bone mineral density (BMD) less...
<div>Abstract<p>Although bevacizumab (BEV) plays a key role in ovarian cancer (OC) treatment, BEV resistance is often observed clinical settings. This study aimed to identify the genes responsible for resistance. C57BL/6 mice inoculated with ID-8 murine OC cells were treated anti-VEGFA antibody or IgG (control) twice weekly four weeks. The sacrificed, then, RNA was extracted from disseminated tumors. qRT-PCR assays performed angiogenesis-related and miRNAs that altered by...
<p>Supplementary Figure 2 shows that PAI-1 enhanced in vitro tube formation not only the absence of anti-VEGFA antibody but also presence antibody.</p>
<p>Supplementary Figure 6 shows that the transduction of miR-143-3p does not attenuate in vitro tube formation HUVECs incubated with culture media SKOV3ip1 cells.</p>
<p>Supplementary Figure 5 shows thatVEGF induces in vitro tube formation HUVECs at a concentration of ≥ 3 ng/ml, whereas treatment with 100 µg/ml anti-VEGFA antibody attenuates the effects VEGF.</p>
<p>Supplementary Figure 1 shows Kaplan–Meier plotter analysis of genes that were upregulated during anti-VEGFA treatment.</p>
<p>Supplementary Figure 3 shows the correlation analysis between miR-10a-5p expression and PAI-1 concentration.</p>
<p>Supplementary Figure 5 shows thatVEGF induces in vitro tube formation HUVECs at a concentration of ≥ 3 ng/ml, whereas treatment with 100 µg/ml anti-VEGFA antibody attenuates the effects VEGF.</p>
<p>Supplementary Figure 7 shows that the transduction of miR-143-3p did not affect tumor growth in a murine model ovarian cancer.</p>
<p>Supplementary Figure 8 shows the representative images of immunohistochemical staining a human normal kidney for PAI-1 and CD31.</p>
<p>Supplementary Figure 7 shows that the transduction of miR-143-3p did not affect tumor growth in a murine model ovarian cancer.</p>
<p>Supplementary Figure 3 shows the correlation analysis between miR-10a-5p expression and PAI-1 concentration.</p>
<p>Supplementary Figure 6 shows that the transduction of miR-143-3p does not attenuate in vitro tube formation HUVECs incubated with culture media SKOV3ip1 cells.</p>
<p>Supplementary Figure 2 shows that PAI-1 enhanced in vitro tube formation not only the absence of anti-VEGFA antibody but also presence antibody.</p>
<p>Supplementary Figure 1 shows Kaplan–Meier plotter analysis of genes that were upregulated during anti-VEGFA treatment.</p>
<p>Supplementary Figure 4 shows that the knockdown of VEGFA significantly inhibited expression level miR-143-3p, followed by upregulation PAI secretion from OC cells.</p>
<p>Supplementary Figure 8 shows the representative images of immunohistochemical staining a human normal kidney for PAI-1 and CD31.</p>
<p>Supplementary Figure 4 shows that the knockdown of VEGFA significantly inhibited expression level miR-143-3p, followed by upregulation PAI secretion from OC cells.</p>
<div>Abstract<p>Although bevacizumab (BEV) plays a key role in ovarian cancer treatment, BEV resistance is often observed clinical settings. This study aimed to identify the genes responsible for resistance. C57BL/6 mice inoculated with ID-8 murine cells were treated anti-VEGFA antibody or IgG (control) twice weekly 4 weeks. The sacrificed, then, RNA was extracted from disseminated tumors. qRT-PCR assays performed angiogenesis-related and miRNAs that altered by treatment....
<p>Supplementary Figure 6 shows that the transduction of miR-143-3p does not attenuate in vitro tube formation HUVECs incubated with culture media SKOV3ip1 cells.</p>
<div>Abstract<p>Although bevacizumab (BEV) plays a key role in ovarian cancer treatment, BEV resistance is often observed clinical settings. This study aimed to identify the genes responsible for resistance. C57BL/6 mice inoculated with ID-8 murine cells were treated anti-VEGFA antibody or IgG (control) twice weekly 4 weeks. The sacrificed, then, RNA was extracted from disseminated tumors. qRT-PCR assays performed angiogenesis-related and miRNAs that altered by treatment....
<p>Supplementary Figure 5 shows thatVEGF induces in vitro tube formation HUVECs at a concentration of ≥ 3 ng/ml, whereas treatment with 100 µg/ml anti-VEGFA antibody attenuates the effects VEGF.</p>
<p>Supplementary Figure 1 shows Kaplan–Meier plotter analysis of genes that were upregulated during anti-VEGFA treatment.</p>